Ann Dandurand

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · Nephrology Dialysis Transplantation · 2017 · 180 citations · Full text

Medicine, Nephrology, Pharmacology +13

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Vicente E. Torres, Arlene B. Chapman, Olivier Devuyst et al. · Nephrology Dialysis Transplantation · 2017 · 59 citations · Full text

Medicine, Nephrology, Pharmacology +13

Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease

Djalila Mekahli, Lisa M. Guay‐Woodford, Melissa A. Cadnapaphornchai et al. · Clinical Journal of the American Society of Nephrology · 2023 · 39 citations · Full text

Pharmacy, Pediatrics, Pharmacotherapy +14

Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial

Franz Schaefer, Djalila Mekahli, Francesco Emma et al. · European Journal of Pediatrics · 2019 · 36 citations · Full text

Medicine, Pediatrics, Pharmacotherapy +14

Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults

Susan E. Shoaf, Patricia Bricmont, Ann Dandurand · European Journal of Clinical Pharmacology · 2017 · 30 citations · Full text

Medicine, Endocrinology, Pharmacology +8